$5.02 1.2%
VNDA Stock Price vs. AI Score
Data gathered: September 7

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.


Vanda Pharmaceuticals
Price $5.02
Target Price Sign up
Volume 467,370
Market Cap $296M
Year Range $3.47 - $6.5
Dividend Yield 0%
PE Ratio 126
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q2 '2450M44M6.5M-4.5M-8.3M-0.080
Q1 '2447M36M12M-4.1M-7.2M-0.072
Q4 '2345M28M17M-2.4M-6.1M-0.040
Q3 '2339M28M11M140,000-5.6M0.002
Q2 '2346M32M14M1.5M-2.5M0.030

Insider Transactions View All

Moran Kevin Patrick filed to sell 228,763 shares at $5.9.
July 29 '24
Birznieks Gunther filed to sell 313,569 shares at $4.1.
March 6 '24
Moran Kevin Patrick filed to sell 231,014 shares at $4.2.
March 6 '24
Wijkstrom Joakim filed to sell 129,789 shares at $4.2.
March 6 '24
Williams Timothy filed to sell 196,825 shares at $4.2.
March 6 '24

What is the Market Cap of Vanda Pharmaceuticals?

The Market Cap of Vanda Pharmaceuticals is $296M.

What is Vanda Pharmaceuticals' PE Ratio?

As of today, Vanda Pharmaceuticals' PE (Price to Earnings) ratio is 126.

What is the current stock price of Vanda Pharmaceuticals?

Currently, the price of one share of Vanda Pharmaceuticals stock is $5.02.

How can I analyze the VNDA stock price chart for investment decisions?

The VNDA stock price chart above provides a comprehensive visual representation of Vanda Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Vanda Pharmaceuticals shares. Our platform offers an up-to-date VNDA stock price chart, along with technical data analysis and alternative data insights.

Does VNDA offer dividends to its shareholders?

As of our latest update, Vanda Pharmaceuticals (VNDA) does not offer dividends to its shareholders. Investors interested in Vanda Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Vanda Pharmaceuticals?

Some of the similar stocks of Vanda Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.